Hallucinogens, serotonin and obsessive-compulsive disorder

Journal of Psychoactive Drugs

Volumn 30, Issue 4, 1998, Pages 359-366

  Delgado, Pedro L ^a   Moreno, Francisco A ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Adverse effects; Antidepressant; Anxiety disorder; Serotonin receptors; Serotonin reuptake inhibitor

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; CLOZAPINE; FLUVOXAMINE; LYSERGIDE; MESCALINE; NEFAZODONE; OLANZAPINE; PSILOCYBINE; PSYCHEDELIC AGENT; RISPERIDONE; RITANSERIN; SEROTONIN 2C RECEPTOR; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; TRAZODONE;

ARTICLE; COGNITIVE DEFECT; DRUG BINDING; DRUG POTENCY; DRUG SAFETY; DYSPHORIA; HUMAN; HUMAN TISSUE; OBSESSION; PATHOPHYSIOLOGY; PSYCHOPHARMACOLOGY; PSYCHOSIS; SEROTONIN RELEASE; SEROTONINERGIC SYSTEM; SUICIDAL BEHAVIOR;

EID: 0032428621     PISSN: 02791072     EISSN: 21599777     Source Type: Journal    
DOI: 10.1080/02791072.1998.10399711     Document Type: Article

References (63)

1. Abraham, H. 1983. Visual phenomenology of the LSD flashback. Archives of General Psychiatry 40:884-89.
2. Abraham, H.D.; Aldridge, A.M. & Gogia, P. 1996. The psychopharmacology of hallucinogens. Neuropsychopharmacology 14 (4): 285-98.
3. Abraham, H.D. & Mamen, A. 1996. LSD-Iike panic from risperidone in post-LSD visual disorder. Journal of Clinical Psychopharmacology 16 (3): 238-41.
4. Aghajanian, G.K. 1994. Serotonin and the action of LSD in the brain. Psychiatric Annals 24 (3): 137-41.
5. Aghajanian, G.K. 1980. Mescaline and LSD facilitate the activation of locus coeruleus neurons by peripheral stimuli. Brain Research 186:492-98.
6. lh Ed. Washington, D.C.: American Psychiatric Association.
7. Barr, L.C.; Goodman, W.K.; McDougle, C.J.; Delgado, P.L.; Heninger, G.R.; Charney, D.S. & Price, L.H. 1994. Tryptophan depletion in patients with obsessive-compulsive disorder who respond to serotonin reuptake inhibitors. Archives of General Psychiatry 51:309-17.
8. Bar, L.C.; Goodman, W.K. & Price, L.H. 1993. TOe serotonin hypothesis of obsessive-compulsive disorder. International Clinical Psychopharmacology 8 (Suppl. 2): 79-82.
9. Benkelfat, C.; Murphy, D.L.; Zohar, J.; Hill, J.L.; Grover, G. & Inset, T.R. 1989. Clomipramine inobsessive-compulsivedisorder: Further evidence for a serotonergic mechanism of action. Archives of General Psychiatry 46 (1): 23-28.
10. Blacker, K.H.; Jones, R.T.; Stone, G.C. & Pfefferbaum, D. 1968. Chronic users of LSD: The “acidheads.” American Journal of Psychiatry 125:341-51.
11. Blier, P. & de Montigny, C. 1994. Current advances in the treatment of depression. Trends in the Pharmacological Sciences 15:220-26.
12. Bonson, K.R.; Buckholtz, J.W. & Murphy, D.L. 1996. Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans. Neuropsychopharmacology 14 (6): 425-36.
13. Brandrup, E. & Vanggaard, T. 1977. LSD treatment in a severe case of compulsive neurosis. Acta Psychiatrica Scandinavica 55:127-41.
14. 2 receptors in rat brain. Neuropsychopharmacology 3:137-48.
15. Cohen, S. 1960. Lysergic acid diethylamide: Side effects and complications. Journal of Nervous and Mental Disease 130:3040.
16. Cohen, S. & Edwards, A. 1969. LSD and organic brain impairment. Drug Dependency 2:1-4.
17. Cummings, J.L. 1993. Frontal-subcortical circuits and human behavior. Archives of Neurology 50:873-80.
18. Darmani, N.A.; Martin, B.R. & Glennon, R.A. 1992. Behavioral evidence for differential adaptation of the serotonergic system after acute and chronic treatment with (+)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) or ketanserin. Journal of Pharmacology and Experimental Therapeutics 262:692-98.
19. Delgado, P.L.; Charney, D.S.; Price, L.H.; Aghajanian, G.K.; Landis, H. & Heninger, G.R. 1990a. Serotonin function and the mechanism of antidepressant action: Reversal of antidepressant induced remission by rapid depletion of plasma tryptophan. Archives of General Psychiatry 47:411-18.
20. Delgado, P.L.; Goodman, W.K.; Price, L.H.; Charney, D.S. & Heninger, G.R. 1990b. Huvoxamine treatment of a case ofcombined Tourette's and obsessive compulsive disorder. British Journal of Psychiatry 157:762-65.
21. 2 receptor and fluvoxamine effect in obsessive-compulsive disorder. Human Psychopharmacology 7:287-89.
22. Foa, E. B. & Kozak, M.J. 1992. DSM-IV field trial: obsessive compulsive disorder. American Journal of Psychiatry 152:90-6.
23. Freedman, D.X. 1968. On the use and abuse of LSD. Archives of General Psychiatry 18:330-47.
24. Freud, S. 1909 [1963]. Notes from a case of obsessional neurosis. In: P. Rieff (Ed.) Three Case Histories by Sigmund Freud. New York: Collier Books.
25. Ghaemi, S.N.; Zarate, C.A. Jr.; Popli, A.P.; Pillay, S.S. & Cole, J.O. 1995. Is there a relationship between clozapine and obsessive-compulsive disorder? A retrospective chart review. Comprehensive Psychiatry 36:267-70.
26. Glennon, R.A. & Dukat, M. 1995. Serotonin receptor subtypes. In: F.E. Bloom & D.J. Kupfer (Eds.) Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press.
27. 2 serotonin receptors: Evidence for a lack of selectivity. Journal of Medicinal Chemistry 35:734-40.
28. 2 involvement in the mechanism of action of hallucinogenic agents. Life Science 35:2505-11.
29. Goodman, W.K.; Kozak, M.J.; Liebowitz, M. & White, K.L. 1996. Treatment of obsessive-compulsive disorder with fluvoxamine— A multicentre, double-blind, placebo-controlled trial. Iniernaiioml Clinical Psychopharmacology II (1): 21-9.
30. Goodman, W.K.; McDougle, C.J.; Price, L.H.; Barr, L.C.; Hills, OF.; Caplik, J.F.; Charney, D.S. & Heninger, G.R. 1993. m-Chrorophenylpiperazine in patients with obsessive-compulsive disorder: absence of symptom exacerbation. Biological Psychiatry 38 (3): 138-49.
31. Goodman, W.K.; Price, L.H.; Delgado, PL.; Palumbo, J.; Krystal, J.H.; Nagy, L.M.; Rasmussen, S.A.; Heninger, G.R. & Charney, D.S. 1990. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Archives of General Psychiatry 47:577-85.
32. Grinspoon, L. & Bakalar, J.B. 1981. Psychedelic Drugs Reconsidered. New York: Basic Books.
33. Hanes, K.R. 1996. Serotonin, psilocybin, and body dysmorphic disorder: A case report. Journal of Clinical Psychopharmacology 16:18889.
34. Hofmann, A. 1959. Psychotomimetic drugs, chemical and pharmacological aspects. Acta Physiologica Pharmacologica Nederlandica 8:240-58.
35. Hollander, E.; DeCaria, C.M.; Nitescu, A.; Gully, R.; Suckow, R.F.; Cooper, T.B.; Gorman, J.M.; Klein, D.F. & Liebowitz, M.R. 1992. Serotonergic function in obsessive-compulsive disorder: Behavioral and neuroendocrine responses to oral m-CPP and fenfluramine in patients and healthy volunteers. Archives of General Psychiatry 49:21-8.
36. Horowitz, M.J. 1969. Flashbacks: Recurrent intrusive images after the use of LSD. American Journal of Psychiatry 126:565-69.
37. Leonard, H.L. & Rapoport, J.L. 1987. Relief of obsessive-compulsive symptoms by LSD and psilocin. American Journal of Psychiatry 144 (9): 1239-40.
38. Levkovitch, Y.; Kronnenberg, Y. & Gaoni, B. 1995. Can clozapine trigger OCD? Journal of the American Academy of Child and Adolescent Psychiatry 34:263.
39. Malleson, N. 1971. Acute adverse reactions to LSD in clinical and experimental use in the United Kingdom. British Journal of Psychiatry 118:229-230.
40. McDougle, C.J. 1997. Update on pharmacological management of OCD: Agents and augmentation. Jourmlof Clinical Psychiatry 58 (Suppl. 12): 11-17.
41. McDougle, C.J.; Barr, L.C.; Goodman, W.K.; Pelton, G.H.; Aronson, S.C.; Anand, A. & Price, L.H. 1995. Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder. American Journal of Psychiatry 152: 1812-14.
42. McDougle, C.J.; Epperson, C.N. & Price, L.H. 1996. Obsessive-compulsive symptoms with neuroleptics. Journal of the American Academy of Child and Adolescent Psychiatry 35:837.
43. McGlothlin, W.H. & Arnold, D.O. 1971.LSDrevisited: A ten-year follow-up of medical LSD use. Archives of General Psychiatry 24:35-49.
44. Mindus, P.; Rasmussen, S.A. & Lindquist, C. 1994. Neurosurgical treatment for refractory obsessive-compulsive disorder: implications for understanding frontal lobe function. Journal of Neuropsychiatry and Clinical Neuroscience 6:467-77.
45. Modell, J.G.; Mountz, J.M.; Curtis, G. & Greden, J.F. 1989. Neurophysiologic dysfunction in basal ganglia/limbic striatal and thalamo-cortical circuits as a pathogenetic mechanism of obsessive-compulsive disorder. Journal of Neuropsychiatry I:27-36.
46. Moreno, F.A. & Delgado, P.L. 1997. Hallucinogen-induced relief of obsessions and compulsions. American Journal of Psychiatry 154 (7): 1037-38.
47. Neill, J.R. 1987. “More than medical significance”: LSD and American psychiatry 1953 to 1966. Journal of Psychoactive Drugs 19 (I): 39-45.
48. Pauls, D.L.; Alsobrook, J.P.; Phil, M.; Goodman, W.; Rasmussen, S. & Leckman, J.F. 1995. A family study of obsessive-compulsive disorder. American Journal of Psychiatry 152:76-84.
49. Pigott, T.A.; Grady, T.A.; L'Heureux, F.; Bernstein, S.; Rubinstein, C.S. & Murphy, D.L. 1993. A comparison of the behavioral effects of oral versus intravenous mCPP administration in OCD patients and the effect of metergoline prior to iv mCPP. Biological Psychiatry 33:3-14.
50. Rapoport, J.L. 1988.The neurobiology of obsessive-compulsive disorder. Journal of the American Medical Association 260:2888-90.
51. Rasmussen, S.A. & Eisen, J.L. 1990. Epidemiology of obsessive compulsive disorder. Journal of Clinical Psychiatry 51 (Suppl. 8): 20-23.
52. Regier, D.A.; Boyd, J.H.; Burke, J.D.; Rae, D.S.; Myers, J.K.; Kramer, M.; Robins, L.N.; George, L.K.; Karno, M. & Locke, B.Z. 1988. One-month prevalence of mental disorders in the United States. Archives of General Psychiatry 45:977-86.
53. Riedlinger, T.J. & Riedlinger, J.E. 1994. Psychedelic and entactogenic drugs in the treatment of depression. Journal of Psychoactive Drugs 26 (1): 41-55.
54. Robins, L.N.; Helzer, J.E.; Weissman, M.M.; Orvaschel, H.; Gruenberg, E.; Burke, J.D. & Regier, D.A. 1984. Lifetime prevalence of specific psychiatric disorders in three sites. Archives of General Psychiatry 41:949.
55. Savage, C. 1952. Lysergic acid diethylamide (LSD-25): A clinical-psychological study. American Journal of Psychiatry I 08:896-900.
56. Savage, C.; Jackson, D. & Terrill, J. 1962. LSD, transcendence, and the new beginning. Journal of Nervous and Mental Disease 135:42539.
57. Smith, D.E. & Seymour, R.B. 1994. LSD: History and toxicity. Psychiatric Annals 24 (3): 145-47.
58. Stoll, W.A. 1947. Lysergsaure-diathylamid, ein phantastikum aus der mutterknorngruppe. Schweizer Archiv fur Neurologie und Psychiatrie 60:279-323.
59. Strassman, R.J. 1995. Hallucinogenic drugs in psychiatric research and treatment: Perspectives and prospects. Journal of Nervous and Mental Disease 183 (3): 127-38.
60. Strassman, R.J. 1992. Human hallucinogen interactions with drugs affecting serotonergic ne^^^asmission. Neuropsychopharmacology 7:241-43.
61. Strassman, R.J. 1984. Adverse reactions to psychedelic drugs. A review of the literature. Journal of Nervous and Mental Disease 172:57795.
62. Strassman, R.J.; Qualls, C.R. & Berg, L.M. 1996. Differential tolerance to biological and subjective effects of four closely spaced doses of N, N-Dirnethyltryptamine in humans. Biological Psychiatry 39:78495.
63. Swedo, S.E.; Leonard, H.L.; Mittleman, B.B.; Allen, A.J.; Rapoport, J.L.; Dow, S.P.; Kanter, M.E.; Chapman, F. & Zabriskie, J. 1997. Identification of children with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections by a marker associated with rheumatic fever. American Journal of Psychiatry 154:110-12.